Statement: the primary trial participants recieve less than 300mg/m^2 doses of Pralatrexate. cd4 negative is an indication that cd4 expression has not been detected in a sample.
Primary_evidence: INTERVENTION 1:    Pralatrexate   Study drug 190 mg/m^2 for 2 to 4 weeks.